Skip to main content
. 2013 Dec 6;9(3):404–415. doi: 10.4161/epi.27386

Table 3. Odds ratios and 95% confidence intervals for bladder cancer risk and LINE-1%5mC.

PLCO ATBC
Characteristics
All Subjects		 N Case N Control OR2 95% CI2 P2 Characteristic
All Male Smokers		 N
Case		 N Control OR2 95% CI2 P2
Q11 68 178 REF - - Q11 49 195 REF - -
Q2 69 151 1.29 0.85–1.97 0.23 Q2 86 194 1.74 1.15–2.63 0.01
Q3 96 180 1.53 1.03–2.28 0.04 Q3 123 195 2.61 1.75–3.90 1.1x10−5
Q4 66 167 1.23 0.80–1.89 0.34 Q4 133 194 2.78 1.85–4.19 3.8X10−6
P-trend         0.20 P-trend         8.7X10−7
Q1 68 178 REF - - Q1 49 195 REF - -
Q2–4 231 498 1.36 0.96–1.92 0.08 Q2–4 342 583 2.31 1.62–3.30 1.8X10−6
Gender                      
Male Q1 49 141 REF - - NA          
Q2–Q4 193 419 1.48 1.00–2.20 0.05            
Female Q1 19 37 REF - -            
Q2–Q4 38 79 1.11 0.51–2.42 0.79            
P-interaction         0.33            
Age at blood draw-years                
55–64 Q1 21 58 REF     50–65 Q1 40 159 REF - -
Q2–Q4 85 195 1.38 0.75–2.56 0.30 Q2–Q4 202 333 2.35 1.57–3.53 <0.001
65–79 Q1 47 120 REF     65–70 Q1 9 36 REF - -
Q2–Q4 146 303 1.42 0.92–2.18 0.11 Q2–Q4 140 250 2.34 1.06–5.15 0.04
P-interaction         0.96 P-interaction         0.75
Years between blood draw and case diagnosis/control selection    
≤4 Q1 69 94 REF - - ≤4 Q1 10 52 REF - -
Q2–Q4 37 311 1.57 0.96–2.57 0.07 Q2–Q4 107 174 3.16 1.49–6.67 0.003
5–13 Q1 116 84 REF - - 5–16 Q1 39 143 REF - -
Q2–Q4 77 187 1.19 0.71–2.01 0.51 Q2–Q4 235 409 2.15 1.42–3.24 <0.001
P-interaction         0.42 P-interaction         0.33
Ever/never smoking         Ever/never smoking        
Never Q1 28 71 REF - - NA          
Q2–Q4 78 233 0.82 0.47–1.45 0.50            
Ever Q1 47 107 REF - -            
Q2-Q4 146 265 1.82 1.18–2.79 0.01            
P-interaction         0.08            
Pack-years of smoking         Pack-years of smoking        
1–40 Q1 24 67 REF - - 1–40 Q1 30 143 REF - -
Q2–Q4 84 169 1.71 0.94–3.08 0.08 Q2–Q4 192 383 2.39 1.53–3.74 <0.001
>41 Q1 22 39 REF - - >41 Q1 19 52 REF - -
Q2–Q4 89 91 1.99 1.03–3.83 0.04 Q2–Q4 150 200 2.45 1.3–4.50 0.004
P-interaction         0.58 P-interaction         0.76
Alcohol drinking (drinks per day)       (g per day)          
≤0.5 Q1 36 107 REF - - ≤12.1 Q1 31 94 REF - -
Q2–Q4 130 295 1.43 0.89–2.30 0.14 Q2–Q4 180 305 1.71 1.07–2.76 0.03
>0.5 Q1 32 71 REF - - >12.1 Q1 18 101 REF - -
Q2–Q4 101 203 1.25 0.75–2.07 0.39 Q2–Q4 162 278 3.79 2.13–6.76 <0.001
P-interaction         0.82 P-interaction         0.08
Vegetable intake (servings per day)       (g per day)          
≤5 Q1 40 89 REF - - <749.5 Q1 27 98 REF - -
Q2–Q4 115 246 1.14 0.71–1.84 0.58 Q2–Q4 204 317 2.51 1.54–4.11 <0.001
>5 Q1 28 89 REF - - ≥749.5 Q1 22 97 REF - -
Q2–Q4 116 252 1.69 1.00–2.85 0.05 Q2–Q4 138 266 2.14 1.25–3.66 0.005
P-interaction         0.23 P-interaction         0.73
Fruit intake (servings per day)                  
≤3 Q1 42 97 REF - - <233.1 Q1 28 106 REF - -
Q2–Q4 130 245 1.32 0.83–2.09 0.24 Q2–Q4 211 353 2.53 1.56–4.11 <0.001
>3 Q1 26 81 REF - - >233.1 Q1 21 89 REF - -
Q2–Q4 101 253 1.48 0.85–2.59 0.16 Q2–Q4 131 230 2.37 1.36–4.15 0.002
P-interaction         0.68 P-interaction         0.92
Folate (diet and supplement, mg per day)                
≤539.2 Q1 32 86 REF - - < 346.1 Q1 24 97 REF - -
Q2–Q4 100 252 1.24 0.75–2.05 0.40 Q2–Q4 187 304 2.61 1.56–4.36 <0.001
>539.2 Q1 36 92 REF - - ≥346.1 Q1 25 98 REF - -
Q2–Q4 131 246 1.53 0.93–2.50 0.09 Q2–Q4 155 279 1.99 1.20–3.31 0.01
P-interaction         0.47 P-interaction         0.49
Vitamin B6 (diet and supplement, mg per day)                
≤3.5 Q1 36 88 REF - - <2.5 Q1 28 106 REF - -
Q2–Q4 105 251 1.19 0.74–1.93 0.48 Q2–Q4 188 294 2.49 1.54–4.05 <0.001
>3.5 Q1 32 90 REF - - ≥2.5 Q1 21 89 REF - -
Q2–Q4 126 247 1.62 0.96–2.72 0.07 Q2–Q4 154 289 2.16 1.24–3.75 0.01
P-interaction         0.25 P-interaction         0.67
Vitamin B12 (diet and supplement, mg per day)                
≤9.1 Q1 36 90 REF - - <11.0 Q1 20 105 REF - -
Q2–Q4 96 251 1.12 0.68–1.82 0.66 Q2–Q4 186 316 3.62 2.11–6.20 <0.001
>9.1 Q1 32 88 REF - - ≥11.0 Q1 29 90 REF - -
Q2–Q4 145 247 1.77 1.06–2.94 0.03 Q2–Q4 156 267 1.63 0.98–2.71 0.06
P-interaction         0.17 P-interaction         0.07
Dietary protein (g per day)                  
≤83.5 Q1 49 94 REF - - <94.8 Q1 22 105 REF - -
Q2–Q4 120 244 1.01 0.66–1.56 0.95 Q2–Q4 176 305 2.63 1.56–4.45 <0.001
>83.5 Q1 19 84 REF - - ≥94.8 Q1 27 90 REF - -
Q2–Q4 111 254 2.32 1.25–4.34 0.01 Q2–Q4 166 278 1.85 1.12–3.05 0.02
P-interaction         0.02 P-interaction         0.30
Dietary methionine (mg per day)                  
≤1.8 Q1 44 95 REF - - <2.1 Q1 25 101 REF - -
Q2–Q4 122 242 1.20 0.77–1.86 0.43 Q2–Q4 184 308 2.43 1.46–4.03 0.001
>1.8 Q1 24 83 REF - - ≥2.1 Q1 24 94 REF - -
Q2–Q4 109 256 1.65 0.93–2.93 0.09 Q2–Q4 158 275 2.06 1.23–3.45 0.01
P-interaction         0.29 P-interaction         0.69

N, number; OR, odds ratio; CI, confidence interval; NA, not applicable; mg, milligrams; g, grams; dx, diagnosis; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Cohort. 1Quartile cutpoints were based on sex and study-specific control levels (see methods section). 2Regression models adjusted for age at blood draw, study center, packyears smoking, sex (PLCO), and treatment arm (ATBC).